Chair and Department of Pharmacology, Poznan University of Medical Sciences, Poland; Palliative Medicine In-Patient Unit, University Hospital of Lord's Transfiguration, Poznan University of Medical Sciences, Poland.
Students' Scientific Society, Poznan University of Medical Sciences, Poznań, Poland.
Biomed Pharmacother. 2019 Jun;114:108838. doi: 10.1016/j.biopha.2019.108838. Epub 2019 Apr 10.
The undesired effects of midazolam can be life-threatening. This paper delineates the findings related to the pharmacokinetics, adverse effects and drug-drug interactions as well as associated therapeutic implications for safe midazolam use.
A systematic review of literature was conducted.
The pharmacokinetics of midazolam depends on hepatic and renal functions, fat tissue mass, route and duration of administration, as well as potential drug-drug interactions. Palliative care patients constitute a high-risk group prone to side effects of drugs, due to polytherapy and multi-organ failure.
Midazolam is one of three most frequently administered drugs in palliative care. The indications for its use include anxiety, dyspnea, seizures, vomiting refractory to treatment, agitation, myoclonus, status epilepticus, restlessness, delirium, pruritus, hiccups, insomnia, analgosedation, palliative sedation and preventing or counteracting undesired effects of ketamine.
咪达唑仑的不良反应可能危及生命。本文阐述了咪达唑仑的药代动力学、不良反应和药物相互作用以及相关的治疗意义，以确保咪达唑仑的安全使用。
对文献进行了系统回顾。
咪达唑仑的药代动力学取决于肝肾功能、脂肪组织质量、给药途径和时间，以及潜在的药物相互作用。姑息治疗患者由于多药治疗和多器官衰竭，构成了易发生药物副作用的高风险群体。
咪达唑仑是姑息治疗中最常使用的三种药物之一。其使用指征包括焦虑、呼吸困难、癫痫发作、对治疗无反应的呕吐、躁动、肌阵挛、癫痫持续状态、不安、谵妄、瘙痒、呃逆、失眠、镇痛镇静、预防或对抗氯胺酮的不良反应。
